However, our study indicated that FGF21 might be a better serum biomarker for NAFLD than ALT, though the clinical value of FGF21 as a NAFLD biomarker still need to be validated by further large-scale studies in the general population. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.